Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target
Biomolecules · 04.09.2025 · 15 (9) · 1281
DOI: 10.3390/biom15091281 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 04.09.2025. Verfasst von Jawaria und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering-C (NIBGE), Faisalabad 38000, Pakistan. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Nicotinamide N-Methyltransferase. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development, and Innovation Fund of Hungary.
Abstract (Originalsprache)
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, arising from complex interactions among metabolic, genetic, and environmental factors. Nicotinamide N-methyltransferase (NNMT) has recently emerged as a key metabolic regulator in CVD pathogenesis. By consuming nicotinamide and methyl groups, NNMT perturbs epigenetic, metabolic, and redox pathways that are critical for cardiovascular health. NNMT-mediated NAD+ depletion impairs mitochondrial function, sirtuin (SIRT) activity, redox balance, and energy metabolism, thereby creating a pro-atherogenic environment. NNMT and its product 1-methylnicotinamide (1-MNA) show a complex duality: they modulate SIRT activity—particularly SIRT1 and SIRT3—to influence gluconeogenesis, cholesterol synthesis, lipogenesis, and mitochondrial antioxidant defenses. NNMT upregulation also elevates homocysteine levels, activating pro-inflammatory and pro-oxidative cascades (e.g., TLR4–NF-κB and STAT3–IL-1β). Growing evidence links NNMT to major CVD risk factors, including hyperlipidemia, hypertension, diabetes mellitus, and obesity. Thus, NNMT has a multifaceted role in cardiovascular health: while its enzymatic activity is often pathogenic (via NAD+/SAM consumption and homocysteine production), its metabolite 1-MNA can exert protective effects (via NRF2 activation and anti-thrombotic mechanisms). This duality highlights the need to delineate the molecular processes that balance these opposing actions. Experimental studies using small-molecule NNMT inhibitors and RNA interference have shown promising cardiometabolic benefits in preclinical models, including improved insulin sensitivity, reduced atherosclerosis, and attenuated cardiac dysfunction. However, no clinical trials have yet targeted NNMT specifically in CVD. Future research should clarify the tissue-specific functions of NNMT and translate these insights into novel therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering-C (NIBGE), Faisalabad 38000, Pakistan.
- Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad 45650, Pakistan.
- Department of Biochemistry, Government College University Faisalabad, Faisalabad 38000, Pakistan.
- Heart and Vascular Center, Semmelweis University, 1122 Budapest, Hungary.
ORCID-Profile: Yusra Zarlashat, Edit Dósa
Förderung
- National Research, Development, and Innovation Fund of Hungary
Zitieren
APA
Jawaria, Zarlashat, Y., Philippovich, M., & Dósa, E. (2025). Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target. Biomolecules, 15(9), 1281. https://doi.org/10.3390/biom15091281
Vancouver
Jawaria, Zarlashat Y, Philippovich M, Dósa E. Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target. Biomolecules. 2025;15(9):1281. doi:10.3390/biom15091281
BibTeX
@article{Jawaria2025,
author = {Jawaria and Zarlashat, Yusra and Philippovich, Márton and Dósa, Edit},
title = {Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {9},
pages = {1281},
doi = {10.3390/biom15091281}
}
EUVIMED